2017
DOI: 10.1371/journal.pbio.2001110
|View full text |Cite
|
Sign up to set email alerts
|

How to Use a Chemotherapeutic Agent When Resistance to It Threatens the Patient

Abstract: When resistance to anticancer or antimicrobial drugs evolves in a patient, highly effective chemotherapy can fail, threatening patient health and lifespan. Standard practice is to treat aggressively, effectively eliminating drug-sensitive target cells as quickly as possible. This prevents sensitive cells from acquiring resistance de novo but also eliminates populations that can competitively suppress resistant populations. Here we analyse that evolutionary trade-off and consider recent suggestions that treatme… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

10
184
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
4
4
1

Relationship

1
8

Authors

Journals

citations
Cited by 117 publications
(194 citation statements)
references
References 116 publications
10
184
0
Order By: Relevance
“…In recent years, significant efforts have been devoted to designing evolutionarily sound strategies that balance short-term drug efficacy with the long-term potential to develop resistance. These approaches describe a number of different factors that could modulate resistance evolution, including interactions between bacterial cells (3,4,5,6,7,8), synergy with the immune system (9), spatial heterogeneity (10,11,12,13,14,15), epistasis between resistance mutations (16,17), precise temporal scheduling (18,19,20,21), and statistical correlations between resistance profiles for different drugs (22,23,24,25,26,27,28,29,30,31).…”
Section: Introductionmentioning
confidence: 99%
“…In recent years, significant efforts have been devoted to designing evolutionarily sound strategies that balance short-term drug efficacy with the long-term potential to develop resistance. These approaches describe a number of different factors that could modulate resistance evolution, including interactions between bacterial cells (3,4,5,6,7,8), synergy with the immune system (9), spatial heterogeneity (10,11,12,13,14,15), epistasis between resistance mutations (16,17), precise temporal scheduling (18,19,20,21), and statistical correlations between resistance profiles for different drugs (22,23,24,25,26,27,28,29,30,31).…”
Section: Introductionmentioning
confidence: 99%
“…A number of recent studies illustrate how a deeper understanding of microbial population dynamics can lead to improved strategies for stalling the emergence of resistance. These anti-resistance approaches exploit different features of the population dynamics, including competitive suppression between sensitive and resistance cells (14,15), synergy with the immune system (16), precise timing of growth dynamics or dosing (17,18), responses to subinhibitory drug doses (19), and band-pass response to periodic dosing (10). Resistance-stalling strategies may also exploit spatial heterogeneity (20,21,22,23,24,25), epistasis between resistance mutations (26,27), hospital-level dosing protocols (28,29), and regimens of multiple drugs applied in sequence (28,30,18,31,19,32) or combination (33,34,35,36,37,38,39,40), which may allow one to leverage statistical correlations between resistance profiles for different drugs (41,42,43,44,39,37,45,46,47,48).…”
Section: Introductionmentioning
confidence: 99%
“…Using 387 a general stochastic model which includes variations of both composition and size of 388 the microbial population, we have shed light on the impact of periodic alternations of 389 presence and absence of antimicrobial on the probability that resistance evolves de novo 390 and rescues a microbial population from extinction. The majority of previous studies of 391 periodic antimicrobial treatments [10,[50][51][52][53][54][55] neglect stochastic effects, while they can 392 have a crucial evolutionary impact [13,15], especially on population extinction [18,20]. 393 In addition, established microbial populations are structured, even within a single 394 patient [56], and competition is local, which decreases their effective size, thus making 395 stochasticity relevant.…”
mentioning
confidence: 99%